ATE67507T1 - Immunotoxine, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzungen. - Google Patents

Immunotoxine, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzungen.

Info

Publication number
ATE67507T1
ATE67507T1 AT87401657T AT87401657T ATE67507T1 AT E67507 T1 ATE67507 T1 AT E67507T1 AT 87401657 T AT87401657 T AT 87401657T AT 87401657 T AT87401657 T AT 87401657T AT E67507 T1 ATE67507 T1 AT E67507T1
Authority
AT
Austria
Prior art keywords
immunotoxins
preparation
pharmaceutical compositions
compositions containing
intermediacy
Prior art date
Application number
AT87401657T
Other languages
English (en)
Inventor
Luigi Barbieri
Pierre Casellas
Florenzo Stirpe
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Application granted granted Critical
Publication of ATE67507T1 publication Critical patent/ATE67507T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6819—Plant toxins
    • A61K47/6821—Plant heterodimeric toxins, e.g. abrin or modeccin
    • A61K47/6823—Double chain ricin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/44—Antibodies bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Botany (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT87401657T 1986-07-15 1987-07-15 Immunotoxine, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzungen. ATE67507T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR8610297A FR2601679B1 (fr) 1986-07-15 1986-07-15 Immunotoxines, procede de preparation et compositions pharmaceutiques en contenant
EP87401657A EP0255424B1 (de) 1986-07-15 1987-07-15 Immunotoxine, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Zusammensetzungen

Publications (1)

Publication Number Publication Date
ATE67507T1 true ATE67507T1 (de) 1991-10-15

Family

ID=9337440

Family Applications (1)

Application Number Title Priority Date Filing Date
AT87401657T ATE67507T1 (de) 1986-07-15 1987-07-15 Immunotoxine, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzungen.

Country Status (15)

Country Link
US (1) US4981953A (de)
EP (1) EP0255424B1 (de)
JP (1) JPS63146831A (de)
KR (1) KR880001299A (de)
AT (1) ATE67507T1 (de)
AU (1) AU614263B2 (de)
DE (1) DE3773077D1 (de)
DK (1) DK369287A (de)
ES (1) ES2040269T3 (de)
FR (1) FR2601679B1 (de)
GR (1) GR3003097T3 (de)
IL (1) IL83183A (de)
NZ (1) NZ221065A (de)
PT (1) PT85317B (de)
ZA (1) ZA875176B (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5248606A (en) * 1990-06-11 1993-09-28 Dowelanco Dna encoding inactive precursor and active forms of maize ribosome inactivating protein
US5635384A (en) * 1990-06-11 1997-06-03 Dowelanco Ribosome-inactivating proteins, inactive precursor forms thereof, a process for making and a method of using
US5191066A (en) * 1990-12-07 1993-03-02 Abbott Laboratories Site-specific conjugation of immunoglobulins and detectable labels
US6749853B1 (en) 1992-03-05 2004-06-15 Board Of Regents, The University Of Texas System Combined methods and compositions for coagulation and tumor treatment
US5965132A (en) 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
DE4310142A1 (de) * 1993-03-29 1994-10-06 Boehringer Mannheim Gmbh Immunologisch aktive Konjugate und ein Verfahren zu ihrer Herstellung
US6818213B1 (en) * 1998-07-13 2004-11-16 Board Of Regents, The University Of Texas System Cancer treatment compositions comprising therapeutic conjugates that bind to aminophospholipids
WO2000002587A1 (en) * 1998-07-13 2000-01-20 Board Of Regents, The University Of Texas System Cancer treatment methods using therapeutic conjugates that bind to aminophospholipids
NZ514918A (en) 1999-04-28 2003-11-28 Univ Texas Compositions and methods for cancer treatment by selectively inhibiting VEGF
US6703020B1 (en) 1999-04-28 2004-03-09 Board Of Regents, The University Of Texas System Antibody conjugate methods for selectively inhibiting VEGF
ATE438409T1 (de) * 2000-09-15 2009-08-15 Pasteur Institut Proteinhaltigen vektoren zur einführung von moleküle in cd11b exprimirende zellen
KR100512870B1 (ko) * 2002-10-15 2005-09-07 주식회사 엔지켐 7α-메톡시세팔로스포린 유도체 나트륨염 7수화물의제조방법
WO2015006505A1 (en) 2013-07-09 2015-01-15 Oleksandr Gorbachov Power amplifier with input power protection circuits

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL47372A (en) * 1975-05-27 1979-10-31 Yeda Res & Dev Fab'dimers bound to daunomycin or adriamycin,their preparation and pharmaceutical compositions containing same
JPS5843926A (ja) * 1981-09-08 1983-03-14 Suntory Ltd 選択性制癌剤
FR2566271B1 (fr) * 1984-06-20 1986-11-07 Sanofi Sa Nouveaux conjugues cytotoxiques utilisables en therapeutique et procede d'obtention
PT80662B (en) * 1984-06-20 1986-12-09 Sanofi Sa Process to obtain anti-tumoral glycoprotein modified on its glycidic portions
US4744981A (en) * 1985-10-17 1988-05-17 Neorx Corporation Trichothecene antibody conjugates

Also Published As

Publication number Publication date
ZA875176B (en) 1988-03-30
DE3773077D1 (de) 1991-10-24
KR880001299A (ko) 1988-04-22
PT85317A (fr) 1987-08-01
EP0255424B1 (de) 1991-09-18
EP0255424A1 (de) 1988-02-03
DK369287D0 (da) 1987-07-15
DK369287A (da) 1988-01-16
JPS63146831A (ja) 1988-06-18
ES2040269T3 (es) 1993-10-16
AU614263B2 (en) 1991-08-29
FR2601679B1 (fr) 1990-05-25
NZ221065A (en) 1990-06-26
FR2601679A1 (fr) 1988-01-22
GR3003097T3 (en) 1993-02-17
IL83183A0 (en) 1987-12-31
PT85317B (pt) 1990-04-30
AU7556487A (en) 1988-01-21
IL83183A (en) 1992-05-25
US4981953A (en) 1991-01-01

Similar Documents

Publication Publication Date Title
DE3372175D1 (en) Covalent conjugates of an enzyme and an antibody, and medicinal compositions containing these conjugates
ATE87319T1 (de) Inklusionskomplexe von 7-isopropoxy-isoflavon mit cyclodextrinen, verfahren zu deren herstellung und diese inklusionskomplexe enthaltende pharmazeutische praeparate.
ATE67507T1 (de) Immunotoxine, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzungen.
FI950062A (fi) Proteiinien foroaktivaatio konjugaatiotarkoituksia varten
FR2522967B1 (fr) Conjugues d'haptenes et de muramyl-peptides, doues d'activite immunogene et compositions les contenant
ATE103002T1 (de) Menschlicher monoklonaler antikoerper gegen lymphadenopathie assozierten virus.
KR910021361A (ko) 항궤양 물질
ATE4411T1 (de) Prostaglandin-verbindungen enthaltende pharmazeutische praeparate und verfahren zu deren herstellung.
ATE193534T1 (de) Benzodiazepin-derivate sowie deren konjugate mit proteinen und polypeptiden
PT81429B (pt) Processo para a preparacao de formulacoes ou suspensoes estaveis de medicamentos solidos, contendo 4-hidroxi- ou 4-aciloxi-4-androsteno-3,17-dionas
PT90296A (pt) Processo para a preparacao de anticorpos monoclonais contra pseudomonas aeruginosa e de composicoes farmaceuticas que os contem
SE8304821D0 (sv) Arabinogalaktaner, deras framstellning och kompositioner innehallande desamma
DE69008859T2 (de) Modifizierte menschliche anti-rh(d)-antikörper.

Legal Events

Date Code Title Description
EEFA Change of the company name
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee